RecruitingPhase 1NCT06520319

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma: a Prospective Study

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

20 participants

Start Date

Jun 21, 2023

Study Type

INTERVENTIONAL

Conditions

Medullary Thyroid Carcinoma

Summary

Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two different radioactive imaging tracers (68Ga-MGS5 and 68Ga-DOTATATE) used in PET/CT scans to see which one better detects recurring medullary thyroid cancer. **You may be eligible if...** - You are between 18 and 80 years old (any gender) - You have been pathologically diagnosed with medullary thyroid cancer - You have a confirmed recurrence of the cancer - You are willing to sign informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have claustrophobia (inability to lie in a scanner) - You are unable or unwilling to provide written informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-MGS5

Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.

Locations(1)

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06520319

Related Trials

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

NCT073832461 location

Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

NCT071387161 location